Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder

• Status: Not yet recruiting
• Trial end date: 2023-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research study is to investigate the safety and feasibility of two (2) oral doses of psilocybin when combined with behavioral support for methamphetamine use disorder (MUD). Participants have a diagnosis of mild or moderate methamphetamine use disorder (MUD). Participants can expect to be actively engaged in the study for up to 26 weeks.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Wisconsin, Madison
• Collaborator: Revive Therapeutics, Ltd.
• Treatments: Psilocybin

Criteria

Inclusion Criteria:

• Diagnosis of mild or moderate methamphetamine use disorder with meth use reported for less than 16 days in the past month

Exclusion Criteria:

• Females with positive urine pregnancy at any time point during screening or study participation

• Inadequately treated hypertension, defined as 2 blood pressure readings, 10 minutes apart, of greater than 140/90 mmHg systolic/diastolic

• Current acute coronary syndrome or angina

• History of heart transplant

• Current use of and inability or unwillingness to taper off of medications that may interact with psilocybin

• Current insulin dependence, due to Type I or Type II diabetes